/PRNewswire/ US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21.
A Japanese drug development venture firm has launched the first phase of a clinical trial for a new type of COVID-19 vaccine that can induce sufficient immunity using smaller dosages than existing vaccines.
The key benefit of self-replicating vaccines is their efficiency, as they require only a fraction of the dosage of conventional vaccines to trigger a strong immune response.